Study of thrombinic activation indexes, in patients with lower limb critic ischaemia, before and after prostaglandin E1 therapy

Minerva Cardioangiologica

Volumn 47, Issue 3, 1999, Pages 55-58

  Trifiletti, A ^a   Bartolone, S ^b   Scamardi, R ^b   Pizzoleo, M A ^b   Attina A ^b   Sottilotta, G ^b   Canobbio, V ^b   Soraci, S ^b   Barbera, N ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE

Author keywords

Alprostadil; Arterial occlusive diseases; Peripheral vascular diseases; Thrombin physiology

Indexed keywords

FIBRINOPEPTIDE; PROSTAGLANDIN E1; PROTHROMBIN; THROMBIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FIBRIN FORMATION; HUMAN; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; THROMBIN TIME; THROMBOSIS;

EID: 0033002771     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
2. Dormandy J, Mahir M, Ascady G, Balsano F, De Leeuw P, Blombery P et al. Fate of the patients with chronic leg ischaemia. J Cardiovasc Surg 1989;30:50-7.
3. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, De Gaetano G et al. The PLAT Study Group: hemostatic function in relation to atherothrombotic ischaemic events in vascular patients. Arteroscler Thromb 1992;12:1063-70.
4. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M et al. Increased fibrin turnover and PAI-1 activity as predictors of ischaemic events in arheroselerotic patients: a case-control study. Arterioscler Thromb 1993;13:1412-7.
5. Cofrancesco E, Boschetti C, Cortellaro M, Haemostatic variahles as predictor of ischaemic events in relation to the localization of atherosclerosis in different arterial beds. Fibrinolysis 1993;7(Suppl 1):52-4.
6. Trifiletti A, Barbera N, Pizzoleo MA, Leone G, Lucifora S, Soraci S et al. Haemostatic disorders associated with arterial hypertension and peripheral arterial disease. J Cardiovasc Surg 1995;36(5):483-5.
7. Schror K. Prostaglandine und verwandte Substanzen, Stuttgart: Thieme, 1984.
8. Rudofsky G. Beeinflussung der Kollateralarterien durch E: Prostaglandin E1 infusion. VASA 1987;20 (Suppl):215.
9. Rudofsky G. The effect of intra-arterial and intravenous prostaglandin E1 in a model of ischaemia in healthy volunteers. In: Sinziger H, Rogatti W, editors. Prostaglandin E1 in atherosclerosis. Berlin: Springer Verlag, 1986:4903.
10. Fantone JC, Kunkel SL, Ward PA, Zurier RB. Suppression of human polymorphonuclear leukocyte function after intravenous infusion of prostaglandine E1. Prostaglandins Med 1981;2:195-8.
11. Ney P, Schror K. E-type prostaglandins but not iloprost inhibit plateled activating factor induced generation of leukotriene B4 by human polymorphonuclear leukocytes. Br J Pharmacol 1989;96:186-92.
12. Stiegler H. Metabolic effects of prostaglandin E1 on human skeletal muscle with special regard to the aminoacid metabolism. VASA 1989;28(Suppl.):14-8.